EagleClaw Capital Managment LLC Has $617,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

Key Points

• EagleClaw Capital Management LLC increased its stake in Abbott Laboratories by 75.5%, now holding 4,648 shares valued at approximately $617,000.
• Abbott Laboratories reported $1.26 earnings per share for the quarter, meeting analysts' expectations, with a revenue of $11.14 billion, rising 7.4% year-over-year.
• The firm declared a quarterly dividend of $0.59 per share, representing an annualized yield of 1.9%, with the dividend set for payment on August 15th.

EagleClaw Capital Managment LLC lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 75.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,648 shares of the healthcare product maker's stock after buying an additional 2,000 shares during the quarter. EagleClaw Capital Managment LLC's holdings in Abbott Laboratories were worth $617,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Three Seasons Wealth LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $1,428,000. Kelly Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth about $216,000. Voleon Capital Management LP bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $273,000. Bank Pictet & Cie Europe AG grew its holdings in Abbott Laboratories by 1.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after buying an additional 2,774 shares during the last quarter. Finally, Edge Financial Advisors LLC increased its position in Abbott Laboratories by 3.3% in the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after buying an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $126.16 on Friday. The firm has a market capitalization of $219.50 billion, a P/E ratio of 15.81, a P/E/G ratio of 2.44 and a beta of 0.73. The stock has a fifty day moving average price of $131.86 and a two-hundred day moving average price of $130.26. Abbott Laboratories has a 52-week low of $103.55 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.83%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the company posted $1.14 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada increased their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Evercore ISI raised their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Finally, Raymond James Financial decreased their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research report on Friday, July 18th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.